PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 8 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Active compounds
Mechanism of action
Clinical evidence
Methanolic extract of H. olympicum recovered DNA damage and prevented MMP-9 activation in human dermal fibroblasts irradiated with UVB [PMID:31476441]
Isolated acylphloroglucinols showed antibacterial activity against various staphylococci and enterococci, though they were inactive against Gram-negative bacteria [PMID:21899267, PMID:24119569]
Methanolic extract and specific isolated compounds (olympiforins) demonstrated dose-dependent anti-growth and cytotoxic activity against tumor cell lines including MCF-7 and MDA-MB-231 [PMID:34907704, PMID:37050127]
Safety & adverse effects
Drug interactions
Evidence summary
PubMed sources
- 1.PMID: 34907704 (2020) — Toxicity assessment of Hypericum olympicum subsp. olympicum L. on human lymphocytes and breast cancer cell lines. · Journal of applied biomedicine
- 2.PMID: 31476441 (2020) — Hypericum olympicum L. recovers DNA damage and prevents MMP-9 activation induced by UVB in human dermal fibroblasts. · Journal of ethnopharmacology
- 3.PMID: 37050127 (2023) — Cytotoxic and Antibacterial Prenylated Acylphloroglucinols from Hypericum olympicum L. · Plants (Basel, Switzerland)
- 4.PMID: 21899267 (2012) — Antibacterial acylphloroglucinols from Hypericum olympicum. · Journal of natural products
- 5.PMID: 41155703 (2025) — Polyprenylated Acylphloroglucinols from Hypericum rochelii and Hypericum olympicum-Cytotoxic Effects on Non-Tumorigenic Cell Lines and Antibacterial Potential.